Taligen Therapeutics Overview

  • Founded
  • 2004
Founded
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $479M
Latest Deal Amount

Taligen Therapeutics General Information

Description

Provider of development stage biotechnology services for the treatment of inflammatory diseases. The company is developing therapies that regulate the complement system to treat inflammatory and immune diseases.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Acquirer
Primary Office
  • Cambridge, MA
  • United States
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Taligen Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 28-Jan-2011 $479M 000.00 00000 Completed Generating Revenue
2. Early Stage VC (Series B) 23-Aug-2010 0000 000.00 Completed Generating Revenue
1. Early Stage VC (Series A) 01-Aug-2006 $3.7M $3.7M Completed Product Development
To view Taligen Therapeutics’s complete valuation and funding history, request access »

Taligen Therapeutics Former Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Alta Partners Venture Capital Minority 000 0000 000000 0
Blackstone Life Sciences PE/Buyout Minority 000 0000 000000 0
High Country Venture Venture Capital Minority 000 0000 000000 0
Sanderling Ventures Venture Capital Minority 000 0000 000000 0
University License Equity Holding Corporation Minority 000 0000 000000 0
To view Taligen Therapeutics’s complete investors history, request access »